Flag of the European Union EU Clinical Trials Register Help

Clinical trials for recombinant interferon alfa

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: recombinant interferon alfa. Displaying page 1 of 1.
    EudraCT Number: 2005-000867-24 Sponsor Protocol Number: ALFR-HC-04 Start Date*: 2005-05-23
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION...
    Medical condition: Hepatitis type C chronic
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-003793-26 Sponsor Protocol Number: 3066K1-3311-WW Start Date*: 2008-05-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
    Medical condition: First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) BE (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012010-52 Sponsor Protocol Number: mRCC Start Date*: 2009-08-04
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma
    Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002704-34 Sponsor Protocol Number: HGS1008-C1067 Start Date*: 2007-04-27
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic Hepatitis C (CHC) genotype 2/3.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002703-13 Sponsor Protocol Number: HGS1008-C1060 Start Date*: 2007-03-20
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic hepatitis C (CHC) genotype 1.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002039-34 Sponsor Protocol Number: CABF656B2202 Start Date*: 2008-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed) GR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002022-10 Sponsor Protocol Number: NV21928 Start Date*: 2008-09-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han...
    Medical condition: Chronic hepatitis C Hepatitis C crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000870-63 Sponsor Protocol Number: WV19432 Start Date*: 2007-03-01
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro...
    Medical condition: Chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013442-86 Sponsor Protocol Number: GS-US-196-0116 Start Date*: 2009-10-02
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects w...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019584-10 Sponsor Protocol Number: NV22776 Start Date*: 2010-12-16
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref...
    Medical condition: Hepatitis C Crónica
    Disease: Version SOC Term Classification Code Term Level
    13 10008912 Hepatitis C crónica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-002715-28 Sponsor Protocol Number: NV27779 Start Date*: 2011-12-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPRE...
    Medical condition: Chronic Hepatitis C (CHC), Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004527-31 Sponsor Protocol Number: GS-US-196-0103 Start Date*: 2008-12-12
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and...
    Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002714-37 Sponsor Protocol Number: NV27780 Start Date*: 2011-11-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR...
    Medical condition: Chronic Hepatitis C (CHC), Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019585-90 Sponsor Protocol Number: WV21913 Start Date*: 2011-05-05
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 07:43:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA